Given the recent expansion of treatment options in advanced melanoma, oncologists now have the opportunity to choose among multiple effective and fairly well-tolerated treatment options.

Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of Merkel cell carcinoma.

This NCCN Guidelines Insights report highlights treatment recommendations and updates specific to the management of patients with advanced non-clear cell carcinoma (non-ccRCC) in the 2014 version of the NCCN Guidelines for Kidney Cancer.

The best treatment strategy for patients with locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) remains the subject of considerable debate.

Both 5-FU and oxaliplatin have been used as single agents in patients with colon cancer and severe liver dysfunction, but the combination of these drugs has not been yet investigated.

Most patients with endometrial cancer will present with early-stage disease.

The NCCN Guidelines Insights on Adolescent and Young Adult (AYA) Oncology discuss the fertility and endocrine issues that are relevant to the management of AYA patients with cancer.  Fertility preservation should be an essential part in the treatment of AYA patients with cancer.

Mutational testing has moved to the forefront as an integral component in the management of patients with non–small cell lung cancer (NSCLC).

Lymphoma is a well-recognized complication in patients infected with HIV. Although its incidence has declined since the advent of antiretroviral therapy, it remains higher than in the general population.

Clear evidence is available regarding the wide variation in the quality of cancer care delivered in the United States. These findings led the Institute of Medicine (IOM) in 1999 to call for major changes in cancer care delivery to improve quality and enhance the patient experience.